Literature DB >> 10940883

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity.

H Tighe1, K Takabayashi, D Schwartz, R Marsden, L Beck, J Corbeil, D D Richman, J J Eiden, H L Spiegelberg, E Raz.   

Abstract

Immunostimulatory DNA sequences (ISS) are a potent Th1 adjuvant. We hypothesized that conjugation of ISS to protein antigens would strongly enhance their immunogenicity because both antigen and adjuvant (ISS) would be delivered to the same locale/antigen-presenting cell. To test this hypothesis, we conjugated a 22-mer immunostimulatory oligodeoxynucleotide (ISS-ODN) to two test antigens of differing intrinsic immunogenicity, namely Escherichia coli beta-galactosidase and the HIV-1 envelope glycoprotein gp120. We show that the antigen-ISS conjugates rapidly induce Th1 cells secreting high levels of IFN-gamma, strong CTL activity, and high titer IgG2a and HIV-neutralizing antibodies, exceeding gene and protein vaccination alone or immunization with mixtures of antigen and ISS-ODN. The data suggest that this procedure generates a novel and unique vaccine that rapidly triggers strong humoral and cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940883     DOI: 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  32 in total

1.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

2.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

3.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

Review 4.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

6.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

7.  Formulation of vaccines containing CpG oligonucleotides and alum.

Authors:  Joan A Aebig; Gregory E D Mullen; Gelu Dobrescu; Kelly Rausch; Lynn Lambert; Olubunmi Ajose-Popoola; Carole A Long; Allan Saul; Aaron P Miles
Journal:  J Immunol Methods       Date:  2007-05-11       Impact factor: 2.303

Review 8.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

9.  TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Authors:  Jason Z Oh; Jonathan S Kurche; Matthew A Burchill; Ross M Kedl
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

10.  Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.

Authors:  Alexander S Cheung; Sandeep T Koshy; Alexander G Stafford; Maartje M C Bastings; David J Mooney
Journal:  Small       Date:  2016-03-08       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.